Prognostic test for lung cancer on horizon
This article was originally published in Clinica
The discovery of two gene expression profiles could pave the way to prognostic tests for lung cancer. The researchers, from the Mayo Clinic in Rochester, Minnesota, believe that the tests will lead to "better personalised treatment options" for sufferers of non-small cell lung cancer (NSCLC).
You may also be interested in...
Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.